turbo air m3f24-1-n Introduction Anaplastic lymphoma kinase (ALK) rearranged non-small cell lung carcinoma (NSCLC) has emerged as a distinct entity with growing number of potent ALK tyrosine kinase inhibitors (TKIs).Despite showing durable responses and promising survival rates, resistance to these ensue.This is the largest series of repeat biopsies from patients of ALK-positive NSCLC progressing kicker pro comp 10 on ALK-directed therapy from this part of the world.Using a combinatorial approach of genomics and histology, we describe the spectrum of various resistance mechanisms encountered.